Sandhill Capital Partners LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Sandhill Capital Partners LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,032 shares of the biopharmaceutical company’s stock after selling 10,601 shares during the period. Sandhill Capital Partners LLC’s holdings in Pfizer were worth $2,794,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc purchased a new stake in Pfizer during the 3rd quarter valued at $30,000. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the 4th quarter worth $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 3.8 %

NYSE:PFE traded down $1.01 on Thursday, reaching $25.26. The company’s stock had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $143.04 billion, a price-to-earnings ratio of 70.17, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The stock has a 50 day moving average price of $27.05 and a 200 day moving average price of $28.50.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.14 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.65%. Pfizer’s dividend payout ratio is currently 466.67%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.